Once-Weekly Insulin Is Here. It’s Still Not Reversal.
The FDA just approved the first once-weekly basal insulin for Type 2 diabetes — Novo Nordisk’s Awiqli, greenlit on March 26, 2026 per the FDA Novel Drug Approvals 2026 list, with the U.S. launch expected in the second half of this year. The pitch is simple: one shot a week instead of seven. For the […]
This New GLP-1 Pill Hit 89.6% A1c Goal — It Doesn’t Reverse Diabetes
The American Diabetes Association’s 2026 Scientific Sessions wrapped last week in New Orleans, and the headlines read like a victory lap. A new once-daily oral GLP-1 called elecoglipron — a small-molecule pill, no injection, no fasting window — sent 89.6% of patients in its phase 2b trial to an A1c of 7.0% or below. Up […]
Retatrutide Matches Bariatric Surgery: What Diabetics Should Know
New long-term data from the TRIUMPH-1 extension trial — presented at the American Diabetes Association’s 2026 Scientific Sessions — shows retatrutide drove an average of 30.3% body weight loss a 104 weeks, and 65% of participants dropped below the obesity threshold entirely. That puts a weekly injectable in the same conversation as gastric bypass and […]
Lilly’s GLP-1 Pill Just Beat Oral Ozempic – It Still Won’t Reverse Diabetes
The race for the first true GLP-1 pill just ended — and it wasn’t even close. Eli Lilly’s once-daily oral GLP-1,orforglipron, just published head-to-head Phase 3 data showing it beat oral semaglutide (the pill form ofOzempic) on both A1c and weight loss. The results dropped this week in The Lancet, with a separate Phase 3study […]
ADA 2026: New GLP-1 Drops A1c 2.2% — Now the Hard Question
The American Diabetes Association’s 86th Scientific Sessions wrapped last week in New Orleans, and the loudest headline came from Pfizer’s phase 2b VESPER-2 trial of berobenatide, a once-weekly and once-monthly GLP-1 showing a 2.2% A1c reduction and double-digit weight loss in people with Type 2 diabetes — with no plateau in sight. It’s a real […]
ADA 2026: The New “Miracle” Diabetes Drug Only Drops A1c 2%
The American Diabetes Association just unveiled the data everyone is talking about, and the headlines are loud. Eli Lilly’s retatrutide, a triple-hormone injection, dropped A1c by up to 2.0% and produced roughly 16.8% body-weight loss in adults with Type 2 diabetes. Pharma is calling it a breakthrough. Wall Street is calling it a blockbuster. The […]
GLP-1s Just Got Stronger — Type 2 Diabetes Is Still Winning
Right now, in New Orleans, 12,000 of the world’s top diabetes researchers are gathered at the ADA 2026 Scientific Sessions. The headlines pouring out of that meeting this week are dominated by one thing: GLP-1 drugs got bigger. The 25 mg dose of the latest incretin therapies produced larger A1c reductions. More weight loss. Better […]